Author: lifemolecular

Read more: Publication of IDEAS study aim 1 results shows that Amyloid PET Imaging was associated with changes in clinical management for Medicare beneficiaries with MCI, dementia, cognitive impairment or Alzheimer’s Disease

Readmore: New clinical data of PI-2620 Tau-PET highlight the sensitive detection of Tau pathology in neurodegenerative diseases .

Readmore: Life Molecular Imaging (LMI) and XingImaging announced that production of LMI’s 18F-labeled Tau PET imaging agent PI-2620 has commenced at XingImaging sites in China. 

Readmore: PI-2620 Tau PET tracer production for clinical trial supply has commenced in SOFIE Radiopharmacy Network

Readmore: Following the recent acquisition by Alliance Medical Group, Piramal Imaging is being renamed Life Molecular Imaging

Readmore: Alliance-Medical-completes-the-purchase-of-Piramal-Imaging